Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy

Leuk Res. 2023 Sep:132:107348. doi: 10.1016/j.leukres.2023.107348. Epub 2023 Jun 28.
No abstract available

Keywords: Acute myeloid leukemia; Reinduction; Venetoclax.

Publication types

  • Letter